Sight Sciences (SGHT) Scheduled to Post Quarterly Earnings on Thursday

Sight Sciences (NASDAQ:SGHT) is scheduled to issue its quarterly earnings data after the market closes on Thursday, May 2nd. Analysts expect the company to announce earnings of ($0.29) per share for the quarter. Sight Sciences has set its FY 2024 guidance at EPS.Individual that are interested in participating in the company’s earnings conference call can do so using this link.

Sight Sciences (NASDAQ:SGHT) last announced its earnings results on Thursday, March 7th. The company reported ($0.22) EPS for the quarter, beating analysts’ consensus estimates of ($0.35) by $0.13. Sight Sciences had a negative net margin of 68.53% and a negative return on equity of 41.94%. The business had revenue of $18.75 million during the quarter, compared to analysts’ expectations of $18.70 million. During the same period in the prior year, the company earned ($0.35) earnings per share. On average, analysts expect Sight Sciences to post $-1 EPS for the current fiscal year and $-1 EPS for the next fiscal year.

Sight Sciences Trading Up 10.2 %

Shares of SGHT opened at $5.82 on Tuesday. Sight Sciences has a fifty-two week low of $1.04 and a fifty-two week high of $11.20. The firm has a 50-day simple moving average of $5.00 and a 200-day simple moving average of $4.14. The company has a current ratio of 13.29, a quick ratio of 12.65 and a debt-to-equity ratio of 0.26.

Wall Street Analyst Weigh In

Separately, Needham & Company LLC reaffirmed a “hold” rating on shares of Sight Sciences in a research report on Wednesday, April 10th. One equities research analyst has rated the stock with a sell rating, five have assigned a hold rating and one has issued a buy rating to the company. According to MarketBeat, the stock presently has a consensus rating of “Hold” and an average target price of $4.60.

Insider Buying and Selling

In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of Sight Sciences stock in a transaction that occurred on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total value of $51,424.84. Following the sale, the chief financial officer now owns 426,248 shares of the company’s stock, valued at approximately $2,165,339.84. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through the SEC website. In other Sight Sciences news, CFO Alison Bauerlein sold 10,123 shares of the firm’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total value of $51,424.84. Following the completion of the sale, the chief financial officer now owns 426,248 shares of the company’s stock, valued at $2,165,339.84. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink. Also, CEO Paul Badawi sold 12,571 shares of the company’s stock in a transaction on Wednesday, April 3rd. The stock was sold at an average price of $5.08, for a total transaction of $63,860.68. Following the transaction, the chief executive officer now directly owns 5,750,729 shares in the company, valued at $29,213,703.32. The disclosure for this sale can be found here. Insiders sold 34,129 shares of company stock valued at $173,375 over the last ninety days. Corporate insiders own 27.10% of the company’s stock.

About Sight Sciences

Sight Sciences, Inc, an ophthalmic medical device company, engages in the development and commercialization of surgical and nonsurgical technologies for the treatment of eye diseases. It operates through two segments, Surgical Glaucoma and Dry Eye. The company's products include OMNI Surgical System, an implant-free glaucoma surgery technology indicated to reduce intraocular pressure in adult patients with primary open-angle glaucoma; and SION Surgical Instrument, a manually operated device used in ophthalmic surgical procedures to excise trabecular meshwork.